Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer
Phase 3 Completed
190 enrolled 12 charts
Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery
Phase 3 Completed
305 enrolled 10 charts
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
Phase 3 Completed
3,270 enrolled 16 charts
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy
Phase 3 Completed
2,014 enrolled 16 charts
Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU
Phase 3 Terminated
96 enrolled 16 charts
Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer
Phase 3 Completed
3,436 enrolled
Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only
Phase 1 Completed
37 enrolled
Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer
Phase 2 Completed
18 enrolled 7 charts
Cellular Adoptive Immunotherapy in Treating a Patient Who Has Undergone a Donor Stem Cell Transplant for Breast Cancer That Has Spread to the Lung
Phase 1 Completed
1 enrolled
Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer
Phase 2 Terminated
39 enrolled 8 charts
Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer
Phase 2 Completed
61 enrolled 12 charts
Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer
Phase 2 Completed
37 enrolled
Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery
Phase 1 Terminated
60 enrolled
Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast Cancer
Phase 3 Completed
1,500 enrolled
Trastuzumab or Observation After Combination Chemotherapy and Trastuzumab in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer
Phase 2 Unknown
160 enrolled
Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer
Phase 3 Unknown
2,500 enrolled
Radiation Therapy to the Head in Preventing Brain Metastases in Women Receiving Trastuzumab and Chemotherapy for Metastatic or Locally Advanced Breast Cancer
Phase 3 Completed
390 enrolled
Trastuzumab and Capecitabine in Treating Women With Metastatic Breast Cancer
Phase 2 Completed
75 enrolled
Vinorelbine With or Without Trastuzumab in Treating Women With Progressive Metastatic Breast Cancer
Phase 3 Completed
Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic
Phase 3 Completed
580 enrolled
Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors
Phase 1 Completed
18 enrolled
Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2
Phase 2 Completed
200 enrolled
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Phase 1 Completed
15 enrolled
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
Phase 1 Completed
24 enrolled
Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer
Phase 1 Terminated
50 enrolled
Monoclonal Antibody Plus Chemotherapy in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2
Phase 2 Completed
55 enrolled
Trastuzumab and Pertuzumab in Treating Patients With Unresectable Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Trastuzumab
Phase 2 Completed
37 enrolled
Trastuzumab in Treating Women With HER2-Positive Early Breast Cancer
Phase 3 Unknown
4,000 enrolled
Trastuzumab for 6 Months or 1 Year in Treating Women With Nonmetastatic Breast Cancer That Can Be Removed By Surgery
Phase 3 Completed
3,400 enrolled
Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery
Phase 2 Unknown
94 enrolled